Dientamoeba fragilis: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Taxobox
{{Dientamoebiasis}}
| color = khaki
{{Taxobox| color = khaki
| name = ''Dientamoeba fragilis''
| name = ''Dientamoeba fragilis''
| domain = [[Eukaryote|Eukaryota]]
| domain = [[Eukaryote|Eukaryota]]
Line 13: Line 13:
__NOTOC__
__NOTOC__
{{About0|Dientamoebiasis}}
{{About0|Dientamoebiasis}}
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
{{CMG}}
{{CMG}}


Line 35: Line 36:
''Dientamoeba fragilis'' replicates by [[binary fission]] and moves by [[pseudopodia]]. ''D. fragilis'' feeds by [[phagocytosis]]. The cytoplasm typically contains numerous food [[vacuole]]s that contain ingested debris, including bacteria. Waste materials are eliminated from the cell through digestive vacuoles by [[exocytosis]]. ''D. fragilis'' possesses some flagellate characteristics. In the binucleate form there is a spindle structure located between the nuclei, which stems from certain polar configurations adjacent to a nucleus—these configurations appear to be homologous to hypermastigotes’ atractophores. There is a complex [[Golgi apparatus]]; the nuclear structure of ''D. fragilis'' is more similar to that of flagellated trichomonads than to that of ''Entamoeba''.  Also notable is the presence of [[hydrogenosome]]s, which are also a characteristic of other trichomonads.  
''Dientamoeba fragilis'' replicates by [[binary fission]] and moves by [[pseudopodia]]. ''D. fragilis'' feeds by [[phagocytosis]]. The cytoplasm typically contains numerous food [[vacuole]]s that contain ingested debris, including bacteria. Waste materials are eliminated from the cell through digestive vacuoles by [[exocytosis]]. ''D. fragilis'' possesses some flagellate characteristics. In the binucleate form there is a spindle structure located between the nuclei, which stems from certain polar configurations adjacent to a nucleus—these configurations appear to be homologous to hypermastigotes’ atractophores. There is a complex [[Golgi apparatus]]; the nuclear structure of ''D. fragilis'' is more similar to that of flagellated trichomonads than to that of ''Entamoeba''.  Also notable is the presence of [[hydrogenosome]]s, which are also a characteristic of other trichomonads.  


==Treatment==
==Gallery==


===Antimicrobial Regimen===
<gallery>


:*'''Dientamoebiasis'''<ref>{{citeweb|title=CDC Dientamoeba fragilis|url=http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html}}</ref><ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy 2014 | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2014 | isbn = 978-1930808782 }}</ref><ref>{{Cite journal| doi = 10.1016/j.ijpddr.2012.08.002| issn = 2211-3207| volume = 2| pages = 204–215| last1 = Nagata| first1 = Noriyuki| last2 = Marriott| first2 = Deborah| last3 = Harkness| first3 = John| last4 = Ellis| first4 = John T.| last5 = Stark| first5 = Damien| title = Current treatment options for Dientamoeba fragilis infections| journal = International Journal for Parasitology. Drugs and Drug Resistance| date = 2012-12| pmid = 24533282| pmc = PMC3862407}}</ref>
Image: Dientamoeba fragilis05.jpeg| Iron-hematoxylin stained photomicrograph depicts a binucleated amoebic trophozoite of a Dientamoeba fragilis parasite. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
::* Preferred regimen: [[Iodoquinol]] 650 mg PO tid for 20 days
::* Alternative regimen (1): [[Paromomycin]] 25–35 mg/kg/day PO in three divided doses for 7 days
::* Alternative regimen (2): [[Metronidazole]] 500–750 mg PO tid for 10 days
::* Alternative regimen (3): [[Tetracycline]] 500 mg PO qid for 10 days


:::* 1.1 '''Treatment in pregnancy'''
Image: Dientamoeba fragilis04.jpeg| Photomicrograph reveals the presence of a trichrome-stained, Dientamoeba fragilis parasitic trophozoites in this specimen. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
::::* The use of [[Iodoquinol]] in pregnancy is limited, and risk to the embryo-fetus is unknown, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
::::* Oral dose of [[Paromomycin]] generally is poorly absorbed from the gastrointestinal tract, with minimal, if any, systemic availability.
::::* [[Metronidazole]] is in pregnancy category B. Data on the use of this drug in pregnant women are conflicting. The available evidence suggests use during pregnancy has a low risk of congenital anomalies. May be used during pregnancy in those patients who will clearly benefit from the drug, although its use in the first trimester is generally not advised.
:::* 1.2 '''Treatment during lactation'''
::::* [[Iodoquinol]] should be used with caution in breastfeeding women.
::::* Oral dose of [[Paromomycin]] is unlikely to be excreted in breast milk, and the drug generally is poorly absorbed from the gastrointestinal tract.
::::* [[Metronidazole]] should be used during lactation only if the potential benefit of therapy to the mother justifies the potential risk to the infant.
:::* 1.3 '''Treatment in pediatric patients'''
::::* [[Iodoquinol]] 30–40 mg/kg/day (maximum 2 g) PO in 3 doses for 􏰄20 days. The safety of iodoquinol in children has not been established.
::::* [[Paromomycin]] 25–35 mg/kg/day PO in 3 doses􏰄 for 7 days. The safety of oral dose in children has not been formally evaluated. However, the safety profiles likely are comparable in children and adults.
::::* [[Metronidazole]] 35–50 mg/kg/day PO in 3 doses for􏰄 10 days. The safety in children has not been established, is listed as an antiamebic and antigiardiasis medicine on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
::::* [[Tetracycline]] 40 mg/kg/day (maximum 2 g) PO in 4 doses for􏰄 10 days


Image: Dientamoeba fragilis03.jpeg| Photomicrograph reveals the presence of a trichrome-stained, Dientamoeba fragilis parasitic trophozoites in this specimen. <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
Image: Dientamoeba fragilis01.jpeg| Trichrome-stained photomicrograph reveals the presence of a parasitic Dientamoeba fragilis trophozoite (1150x mag). <SMALL><SMALL>''[http://phil.cdc.gov/phil/home.asp From Public Health Image Library (PHIL).] ''<ref name=PHIL> {{Cite web | title = Public Health Image Library (PHIL) | url = http://phil.cdc.gov/phil/home.asp}}</ref></SMALL></SMALL>
</gallery>
==References==
==References==
{{reflist|2}}
{{reflist|2}}
Line 64: Line 53:
[[Category:Metamonads]]
[[Category:Metamonads]]
[[Category:Parasites]]
[[Category:Parasites]]
[[Category:Infectious Disease Project]]

Latest revision as of 13:56, 10 August 2015

Dientamoebiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Dientamoebiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Case Studies

Case #1

Dientamoeba fragilis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Dientamoeba fragilis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dientamoeba fragilis

CDC on Dientamoeba fragilis

Dientamoeba fragilis in the news

Blogs on Dientamoeba fragilis

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Dientamoeba fragilis

Dientamoeba fragilis
Scientific classification
Domain: Eukaryota
(unranked) Excavata
Phylum: Metamonada
Class: Parabasalia
Order: Trichomonadida
Genus: Dientamoeba
Species: D. fragilis
Binomial name
Dientamoeba fragilis
This page is about microbiologic aspects of the organism(s).  For clinical aspects of the disease, see Dientamoebiasis.

For patient information click here Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dientamoeba fragilis is a single celled parasite that infects the gastrointestinal tract of humans. Trophozoites of D. fragilis characteristically have two nuclei, hence the 'DI' prefix to the genus name. However, the rest of the genus name indicates that it is an ENTeric AMOEBA and not that it is related to intestinal parasites of the genus Entamoeba. The species name refers to the fact that the trophozoite stages are fragile - they do not survive long in the stool after leaving the body of the human host.

Dientamoebiasis

Infection with Dientamoeba fragilis is called Dientamoebiasis and is associated variously with symptoms of abdominal pain, diarrhea, weight loss, and fever.

Phylogenetics

Dientamoeba fragilis is a type of trichomonad. Trichomonads are flagellated organisms but D. fragilis lacks flagella, having secondarily 'lost' them over evolutionary time. Thus, it is an amoeba of flagellate ancestry.

Life Cycle

The life cycle of this parasite has not yet been completely determined, but some assumptions have been made based on clinical data. To date, a cyst stage has not been identified in D. fragilis, and the trophozoite is the only stage found in stools of infected individuals. Like other intestinal parasites, D. fragilis is probably transmitted by the fecal-oral route. In the absence of a cyst form, transmission via helminth eggs (e.g., Ascaris, Enterobius spp.) has been postulated. The rationale for this suggestion is that D. fragilis is closely related to the turkey parasite Histomonas, which is known to be transmitted via the eggs of the helminth Heterakis.

Microbiology

Dientamoeba fragilis replicates by binary fission and moves by pseudopodia. D. fragilis feeds by phagocytosis. The cytoplasm typically contains numerous food vacuoles that contain ingested debris, including bacteria. Waste materials are eliminated from the cell through digestive vacuoles by exocytosis. D. fragilis possesses some flagellate characteristics. In the binucleate form there is a spindle structure located between the nuclei, which stems from certain polar configurations adjacent to a nucleus—these configurations appear to be homologous to hypermastigotes’ atractophores. There is a complex Golgi apparatus; the nuclear structure of D. fragilis is more similar to that of flagellated trichomonads than to that of Entamoeba. Also notable is the presence of hydrogenosomes, which are also a characteristic of other trichomonads.

Gallery

References

  1. 1.0 1.1 1.2 1.3 "Public Health Image Library (PHIL)".